Minassian et al. (UK) assessed the impact of anti-VEGF treatment on the prevalence of sight loss attributable to nAMD against expected demographic changes and concluded that the potential benefit of anti-VEGF would be outweighed by the aging effect and that the overall rate of blindness could increase in the future [19]. The gene discussed is VEGFA; the disease is blindness (disorder).